Cite
HARVARD Citation
Ontaneda, D. et al. (2013). The benefits and risks of alemtuzumab in multiple sclerosis. Expert review of clinical immunology. pp. 189-191. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ontaneda, D. et al. (2013). The benefits and risks of alemtuzumab in multiple sclerosis. Expert review of clinical immunology. pp. 189-191. [Online].